Skip to main content

BMC Cancer

Latest collections open to submissions

EAL small

NEW: Rare cancers

Guest Edited by Atif A. Ahmed and Bruna Samia Dalmasso 

EAL small

NEW: Viral carcinogenesis

Guest Edited by Julian Naipauer

EAL small

NEW: Altered DNA repair mechanisms in tumorigenesis

Guest Edited by Kiyohiro Ando, Pietro Di Fazio, and Zhihua Kang

ACPO small

NEW: Applications of ctDNA and liquid biopsies in precision oncology

Guest Edited by Claude Chelala and Pasquale Pisapia

Editors' Picks

New Content ItemIdentification of DUSP4/6 overexpression as a potential rheostat to NRAS-induced hepatocarcinogenesis


New Content ItemThe survivin-ran inhibitor LLP-3 decreases oxidative phosphorylation, glycolysis and growth of neuroblastoma cells


New Content ItemSynergistic lethality in chronic myeloid leukemia – targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment

New Content Item

Trending BMC Cancer Articles

Click here to view which Articles have been shared most in the last month!

Articles

Most recent articles RSS

View all articles

Most accessed articles RSS

View all articles

Targeted Therapies for Cancer
Guest edited by Prof. Min Li and Dr. Yanis Boumber
Open for submissions

Microbiome and Cancer
Guest edited by Christopher Staley, Jacques Ravel, Sean Devlin
Open for submissions

Cross journal collection: Advances in CAR-T immunotherapy
Guest edited by Profs Marko Radic, Djordje Atanackovic and Tim Luetkens
Collection published: 30 June 2020

Cross journal collection: Precision Oncology
Collection published: 28 August 2019

Browse all BMC Cancer collection contributions


The COUP-1 trial: A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma

The CREATIVE trial: phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer

PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer

OncoSNIPE® Study: Molecular profiles associated with development of resistance in solid cancer patients

The CRCbiome study: a large prospective cohort study examining the role of lifestyle and the gut microbiome in colorectal cancer screening participants

SPARC study: A sexual rehabilitation intervention for women with gynaecological cancer receiving radiotherapy 

MULISARC trial: molecular profiling of advanced soft-tissue sarcomas

THUNDER 2: THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI guided radiotherapy

The ISCON-trial : laparoscopic ischemic conditioning prior to esophagectomy in patients with esophageal cancer and arterial calcifications

The HoSAGE Trial: sarcopenia in older patient with intermediate/high-risk prostate cancer, prevalence and incidence after androgen deprivation therapy

Learn more about study protocols at BMC Cancer here

Aims and Scope


BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions in broad areas of cancer research including molecular and cellular biology, genetics, epidemiology, and clinical trials. Learn more about our scope here. 

Gastric Cancer Awareness Month

July - Sarcoma Awareness Month

Gastric Cancer Awareness Month runs for the whole of November. We hope you will enjoy reading the following study protocol recently published in BMC Cancer designed to prospectively identify 'oligo-metastatic disease', with the aim of proposing novel therapeutic approaches and monitoring strategies.

New Content ItemOligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study

Become an Editorial Board Member

We are recruiting new Editorial Board Members.

Read More

New Content Item (1)

BMC Cancer is celebrating its 20th anniversary! 

Since launching in 2001, we've become established as the largest open access oncology journal in our field. We're proud of our history of making cancer research and methods available to all. We have been looking back at our achievements and highlighted some of the most influential research published in the journal over the past two decades. 

BMC Series Blog

Latest Tweets

Your browser needs to have JavaScript enabled to view this timeline

Submit manuscript

Annual Journal Metrics

  • 2022 Citation Impact
    3.8 - 2-year Impact Factor
    4.3 - 5-year Impact Factor
    1.166 - SNIP (Source Normalized Impact per Paper)
    1.137 - SJR (SCImago Journal Rank)

    2022 Speed
    26 days submission to first editorial decision for all manuscripts (Median)
    148 days submission to accept (Median)

    2022 Usage 
    7,665,706 downloads
    11,097 Altmetric mentions 

Peer-review Terminology

  • The following summary describes the peer review process for this journal:

    Identity transparency: Single anonymized

    Reviewer interacts with: Editor

    Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication

    More information is available here

Follow

Sign up for article alerts and news from this journal

BMC Cancer

ISSN: 1471-2407

Contact us